Recombinant PE Anti-Granzyme B antibody [EPR20129-217] (ab225471)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- PE Rabbit monoclonal [EPR20129-217] to Granzyme B
- Suitable for: ICC/IF
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
Related conjugates and formulations
Overview
-
Product name
PE Anti-Granzyme B antibody [EPR20129-217]
See all Granzyme B primary antibodies -
Description
PE Rabbit monoclonal [EPR20129-217] to Granzyme B -
Host species
Rabbit -
Conjugation
PE. Ex: 488nm, Em: 575nm -
Tested applications
Suitable for: ICC/IFmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein within Human Granzyme B aa 1 to the C-terminus. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P10144 -
Positive control
- ICC/IF: Jurkat cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 1% BSA, PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR20129-217 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab225471 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
1/100.
|
Notes |
---|
ICC/IF
1/100. |
Target
-
Function
This enzyme is necessary for target cell lysis in cell-mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis. -
Sequence similarities
Belongs to the peptidase S1 family. Granzyme subfamily.
Contains 1 peptidase S1 domain. -
Cellular localization
Cytoplasmic granule. Cytoplasmic granules of cytolytic T-lymphocytes and natural killer cells. - Information by UniProt
-
Database links
- Entrez Gene: 3002 Human
- Omim: 123910 Human
- SwissProt: P10144 Human
- Unigene: 1051 Human
-
Alternative names
- C11 antibody
- Cathepsin G like 1 antibody
- Cathepsin G-like 1 antibody
see all
Images
-
ab225471 staining Granzyme B in Jurkat cells. The cells were fixed with 80% methanol (5 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab225471 at 1/100 dilution (shown in green) and ab190573, Rabbit monoclonal to alpha Tubulin (Alexa Fluor® 647), at 1/250 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).
Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab225471 has not yet been referenced specifically in any publications.